Efficacy of dexamethasone and N-acetylcysteine combination in preventing post-embolization syndrome after transarterial chemoembolization in hepatocellular carcinoma

Figure 1 Flow chart of patient screened, recruited, and analyzed in the study (consort diagram). HCC: Hepatocellular carcinoma; NAC: N-acetylcysteine; DEXA: Dexamethasone.

Figure 2 Post-embolization syndrome, liver decompensation and length of hospital stay and adverse events after conventional transarterial chemoembolization. A: Post-embolization syndrome after conventional transarterial chemoembolization; B: Post-conventional transarterial chemoembolization liver decompensation and length of hospital stay; C: Post-conventional transarterial chemoembolization adverse events. NAC: N-acetylcysteine; DEXA: Dexamethasone.